Showing 1 - 14 results of 14 for search 'David G Standaert', query time: 0.03s
Refine Results
-
1
-
2
-
3
-
4
-
5
-
6
-
7
Sex-based differences in the activation of peripheral blood monocytes in early Parkinson disease by Samantha M. Carlisle, Hongwei Qin, R. Curtis Hendrickson, Jordana E. Muwanguzi, Elliot J. Lefkowitz, Richard E. Kennedy, Zhaoqi Yan, Talene A. Yacoubian, Etty N. Benveniste, Andrew B. West, Ashley S. Harms, David G. Standaert
Published 2021-04-01
Article -
8
Internal tremor in people with Parkinson’s Disease: Demographic characteristics and comorbid symptoms by Lana M. Chahine, Lakshmi Arbatti, Abhishek Hosamath, Amy Amara, Karen E. Anderson, Jennifer Purks, Shirley Eberly, Daniel Kinel, Sneha Mantri, Soania Mathur, David Oakes, David G. Standaert, Daniel Weintraub, Ira Shoulson, Connie Marras
Published 2023-01-01
Article -
9
Transcriptional analysis of peripheral memory T cells reveals Parkinson’s disease-specific gene signatures by Rekha Dhanwani, João Rodrigues Lima-Junior, Ashu Sethi, John Pham, Gregory Williams, April Frazier, Yaqian Xu, Amy W. Amara, David G. Standaert, Jennifer G. Goldman, Irene Litvan, Roy N. Alcalay, Bjoern Peters, David Sulzer, Cecilia S. Lindestam Arlehamn, Alessandro Sette
Published 2022-03-01
Article -
10
Pathological α-synuclein recruits LRRK2 expressing pro-inflammatory monocytes to the brain by Enquan Xu, Ravindra Boddu, Hisham A. Abdelmotilib, Arpine Sokratian, Kaela Kelly, Zhiyong Liu, Nicole Bryant, Sidhanth Chandra, Samantha M. Carlisle, Elliot J. Lefkowitz, Ashley S. Harms, Etty N. Benveniste, Talene A. Yacoubian, Laura A. Volpicelli-Daley, David G. Standaert, Andrew B. West
Published 2022-01-01
Article -
11
The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism by Caroline M. Tanner, Steven R. Cummings, Michael A. Schwarzschild, Ethan G. Brown, E. Ray Dorsey, Alberto J. Espay, Nicholas B. Galifianakis, Samuel M. Goldman, Irene Litvan, Nijee Luthra, Nikolaus R. McFarland, Kyle T. Mitchell, David G. Standaert, Douglas C. Bauer, Susan L. Greenspan, James C. Beck, Kenneth W. Lyles
Published 2021-03-01
Article -
12
Evaluation of the safety and immunomodulatory effects of sargramostim in a randomized, double-blind phase 1 clinical Parkinson’s disease trial by Howard E. Gendelman, Yuning Zhang, Pamela Santamaria, Katherine E. Olson, Charles R. Schutt, Danish Bhatti, Bhagya Laxmi Dyavar Shetty, Yaman Lu, Katherine A. Estes, David G. Standaert, Elizabeth Heinrichs-Graham, LuAnn Larson, Jane L. Meza, Matthew Follett, Erica Forsberg, Gary Siuzdak, Tony W. Wilson, Carolyn Peterson, R. Lee Mosley
Published 2017-03-01
Article -
13
Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study by Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala, Maurizio F. Facheris, Victor S. C. Fung
Published 2023-08-01
Article -
14
Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study by Jason Aldred, Eric Freire-Alvarez, Alexander V. Amelin, Angelo Antonini, Bruno Bergmans, Filip Bergquist, Manon Bouchard, Kumar Budur, Camille Carroll, K. Ray Chaudhuri, Susan R. Criswell, Erik H. Danielsen, Florin Gandor, Jia Jia, Thomas E. Kimber, Hideki Mochizuki, Weining Z. Robieson, Amy M. Spiegel, David G. Standaert, Saritha Talapala, Maurizio F. Facheris, Victor S. C. Fung
Published 2023-10-01
Article